PE-Backed Protox Inks $15M

Protox Therapeutics Inc., a Canadian developer of treatment of urological diseases, has sealed a $15 million loan agreement with Oxford Finance. The company, which is backed by Warburg Pincus, will use the money for its late stage drug development program for the treatment of Benign Prostate Hyperplasia. Last fall, Protox inked a commitment from Warburg Pincus to put up to $35 million into the company Protox competed a $10 million first tranche of that financing in November. Protox is traded on the Toronto Stock Exchange.

North AmericaUSBriefs